Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy

• DOI: 10.3389/fcvm.2022.950829
• Publication Date: 2022-08-16T05:52:08Z
• Authors: Shigeru Miyagawa; Satoshi Kainuma; Takuji Kawamura; Kota Suzuki; Yoshito Ito; Hiroko Iseoka; Emiko Ito; Maki Takeda; Masao Sasai; Noriko Mochizuki-Oda; Tomomi Shimamoto; Yukako Nitta; Hiromi Dohi; Tadashi Watabe; Yasushi Sakata; Koichi Toda; Yoshiki Sawa
• Keywords: Ischemic Cardiomyopathy

Despite major therapeutic advances, heart failure, as a non-communicable disease, remains life-threatening disorder, with 26 million patients worldwide, causing more deaths than cancer. Therefore, novel strategies for the treatment of failure continue to be an important clinical need. Based on preclinical studies, allogenic human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) patches have been proposed potential candidate failure. We report implantation allogeneic hiPSC-CM in patient ischemic cardiomyopathy (ClinicalTrials.gov, #jRCT2053190081). The were produced under clinical-grade conditions and displayed cardiogenic phenotypes safety